Tests SHR-1905 injection in adults with moderate-to-severe atopic dermatitis
Tests SHR-1905 injection against a placebo in adults with moderate-to-severe atopic dermatitis.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07211542, who can take part
Where in China
- Dermatology Hospital of Southern Medical UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Trial code
- NCT07211542
- Record updated
- 8 April 2026
- Original description
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-1905 Injection in Patients With Moderate to Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
Inclusion: The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study; At the time of signing the informed consent, the subjects are ≥ 18 years old and ≤ 75 years old, male or female; Have atopic dermatitis at screening.
Exclusion: Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial; Hypersensitivity to the study drug or any ingredient in the study drug; Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD); Has malignancy or has a history of malignancy; Females who are pregnant or lactating.